<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20090901002394N47</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-06-27</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The combined effect of vitamin D and zinc on premenstrual syndrome</public_title>
      <acronym></acronym>
      <scientific_title>The combined effect of vitamin D and Zinc on symptoms of depression, anxiety, premenstrual syndrome (PMS) and Total antioxidant capacity (TAC) in people with premenstrual syndrome (PMS): a randomized, Three-blind clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-07-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>96</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70347</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In order to randomize the samples, first, a list of 96 items is generated by the software available on the internet into two groups of 48 items that are separated by the letters A and B, and this list is provided to the researcher, and the eligible samples are referred to groups A and B are allocated.
The manufacturer of the placebo is asked to put one of the labels A or B on the drug and the other on the placebo by throwing a coin and keep this confidential until the end of the data analysis, and therefore the drugs with one of the letters A or B and placebos are indicated by another letter. According to the randomization table below, the researcher will distribute the drug and placebo according to the order of reference of the samples from packages A or B, so this study will be a three-blind study, that is; The patient, the researcher and the analyst will not be aware of the type of packages received by the samples until the end of the data analysis, Blinding description: The manufacturer of the placebo is asked to put one of the labels A or B on the drug and the other on the placebo by throwing a coin and keep this confidential until the end of the data analysis, and therefore the drugs with one of the letters A or B and placebos are indicated by another letter. According to the randomization table below, the researcher will distribute the drug and placebo according to the order of reference of the samples from packages A or B, so this study will be a three-blind study, that is; The patient, the researcher and the analyst will not be aware of the type of packages received by the samples until the end of the data analysis.</study_design>
      <phase>3</phase>
      <hc_freetext>Premenstrual Syndrome (PMS).</hc_freetext>
      <i_freetext>Intervention 1: intervention group : In this group, 48 people with premenstrual syndrome take a vitamin D supplement of 2000 units and a zinc supplement in the form of zinc gluconate tablets containing 30 mg of elemental zinc every day for up to 8 weeks. These supplements are made by jalinous company. Intervention 2: Control group: In this group, there are 48 people receiving placebo who take capsules completely similar to the original supplements for 8 weeks.The manufactured placebo for vitamin D includes edible paraffin, which is completely similar to vitamin D3 in terms of appearance, color, smell, size, and packaging, and also the placebo for zinc supplementation contains starch. Placebos are made by Galenus company.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Participants privacy</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Esmailpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ibn Sina Student Dormitory, Behdad Shayeg, South Amir Kabir St., end of Jalal El Ahmad Highway, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1461614745</zip>
        <telephone>+98 21 5526 1111</telephone>
        <email>esmailpour.zahraa@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Esmailpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ibn Sina Student Dormitory, Behdad Shayeg, South Amir Kabir St., end of Jalal El Ahmad Highway, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1461614745</zip>
        <telephone>+98 21 5526 1111</telephone>
        <email>esmailpour.zahraa@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Single women with a regular menstrual cycle between 24 and 35 days
The suitable age for the study is 18-30 years old
BMI of the studied women is between 18.5 and 24.9
Not taking any contraceptive pills
Not taking anti-inflammatory, anti-depressant and psychotic drugs
Not doing sports professionally
Not taking vitamin D and zinc supplements for 3 months before starting the study
Willingness, satisfaction and ability to carry out and complete the study and cooperate with the research</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>30 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Being married
Having vitamin D deficiency
Suffering from an endocrine disorder such as thyroid failure, polycystic ovary syndrome and diabetes mellitus
History of gynecological disorders
History of autoimmune diseases
Suffering from chronic and acute diseases (acute or chronic kidney failure, acute or chronic liver failure, chronic inflammatory disease or any known malignancy)
Having irregular menstrual cycles (Less than 24 days and more than 35)
Having stress caused by the death of relatives, surgery or marriage in the previous three months
History of psychiatric diseases</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N94.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Premenstrual tension syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>intervention group : In this group, 48 people with premenstrual syndrome take a vitamin D supplement of 2000 units and a zinc supplement in the form of zinc gluconate tablets containing 30 mg of elemental zinc every day for up to 8 weeks. These supplements are made by jalinous company.</i_keyword>
      <i_keyword>Control group: In this group, there are 48 people receiving placebo who take capsules completely similar to the original supplements for 8 weeks.The manufactured placebo for vitamin D includes edible paraffin, which is completely similar to vitamin D3 in terms of appearance, color, smell, size, and packaging, and also the placebo for zinc supplementation contains starch. Placebos are made by Galenus company</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Depression score in Beck's Depression Inventory. Timepoint: At baseline and after8 weeks. Method of measurement: Beck's Depression Inventory.</prim_outcome>
      <prim_outcome>Depression score in Beck Anxiety Inventory. Timepoint: At baseline and after8 weeks. Method of measurement: Beck Anxiety Inventory.</prim_outcome>
      <prim_outcome>The score of The premenstural symptoms screening tool (PSST). Timepoint: At baseline and after8 weeks. Method of measurement: The premenstural symptoms screening tool (PSST).</prim_outcome>
      <prim_outcome>The levels of total antioxidant capacity. Timepoint: At baseline and after8 weeks. Method of measurement: ELISA Kit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Weight. Timepoint: At baseline and after8 weeks. Method of measurement: Scale.</sec_outcome>
      <sec_outcome>Body mass index. Timepoint: At baseline and after8 weeks. Method of measurement: Calculation.</sec_outcome>
      <sec_outcome>Waist circumference. Timepoint: At baseline and after8 weeks. Method of measurement: Measuring tape.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-24</approval_date>
        <contact_name>Ethics committee of Iran university of medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemat Highway, next to Milad Tower, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
